CSL slashes 15% of workforce and offshoots vaccine division
Australia’s largest pharmaceutical company CSL will reduce its headcount by 15% and spin off its vaccine division in response to …
Post
-
-
Santen and RemeGen sign licence deal for retinal disease injection
Santen Pharmaceutical has signed a licensing agreement with RemeGen for the RC28-E intravitreal injection, a dual-target fusion protein designed to …
-
Merck announces EC approval of Ogsiveo for desmoid tumours
The European Commission (EC) has granted marketing authorisation to SpringWorks Therapeutics, a subsidiary of Merck KGaA, for Ogsiveo (nirogacestat) to …
-
Boehringer Ingelheim marks retinal disease push with $327m licensing deal
Boehringer Ingelheim currently does not have any approved therapies for ophthalmic indications, but the company is looking to change that …
-
Accelerating diagnosis and drug development with better managed datasets
Every aspect of science and research is based on data, and across the globe, labs are producing more data than …
-
Boehringer Ingelheim marks retinal disease push with $327m licensing deal
Boehringer Ingelheim currently does not have any approved therapies for ophthalmic indications, but the company is looking to change that …
-
Accelerating diagnosis and drug development with better managed datasets
Every aspect of science and research is based on data, and across the globe, labs are producing more data than …
-
Novel software solutions can ease transition in an age of clinical supply chain upheaval
The healthcare landscape faces turbulent times. Regulatory pressures, challenges around demand forecasting and an influx of novel therapies are heaping …
-
FDA approves Papzimeos as first therapy for HPV-caused airway disease
The US Food and Drug Administration (FDA) has approved the first treatment for recurrent respiratory papillomatosis (RRP), a rare respiratory …
-
Wegovy becomes first GLP-1RA to gain FDA MASH approval
Danish big pharma Novo Nordisk has been given the go-ahead for its star weight loss drug, Wegovy (semaglutide), in patients …
-
Aquestive signs $75m agreement for launch of Anaphylm
Aquestive Therapeutics has made a strategic funding agreement worth $75m with RTW Investments to support the potential launch of Anaphylm …
-
Sanofi receives orphan status from EMA for rilzabrutinib
Sanofi has received orphan designation from the European Medicines Agency (EMA) for rilzabrutinib, a reversible covalent Bruton’s tyrosine kinase (BTK) …
-
Addressing inefficiencies in clinical trial data management
Data management plays a vital role in the success and reliability of clinical trials by ensuring the integrity, quality and …
-
FDA approves Tonix’s Tonmya to treat fibromyalgia
Tonix Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for Tonmya (cyclobenzaprine HCl sublingual tablets) to …
-
Sanofi’s Tzield secures MHRA go-ahead for type 1 diabetes
Sanofi-owned Aventis Pharma has received approval for its type 1 diabetes (T1D) drug, Tzield (teplizumab), from the UK Medicines and …
